Medium · Jan 2021
A Macromoltek blog post highlighting the team’s science focus and public content cadence, with broader interest in therapeutics and vaccine biology.
Company research
Public company, workplace, funding, and market signals
Overview
Austin-based biotech software company that uses AI and computational modeling to design, humanize, and optimize therapeutic antibodies for biotech and pharma partners.
Primary product
AI-driven antibody discovery and custom antibody design services/platform
Founded
2010
Headquarters
Austin, Texas, United States (2500 W. William Cannon Dr., Suite 204, Austin, TX 78745)
Team size
2-10
Industry
Biotechnology Research
Sub-industry
Computational drug discovery / antibody engineering
Offices
2500 W. William Cannon Dr., Suite 204, Austin, TX 78745, United States
Business model
B2B antibody-design services
custom project partnerships
platform/software access
Funding
Stage
Seed
Total raised
$4.2M
Latest round
Loan · May 2020
Latest amount
$250K
People & investors
Work & culture
Public reviews and company writing describe a small, collaborative, innovative startup environment with flexible/remote collaboration; reviewers also note a steep learning curve, startup-like pace, and weaker work-life balance/salary than they wanted.
Compensation
Public compensation signals are limited. Salary.com estimates average total compensation around $92.7k/year, while an Indeed reviewer said salary is 'currently lacking,' suggesting startup-scale pay.
Product & market
Pricing
Custom B2B service engagements and partnership pricing; historical online workspace access was subscription-like.
Differentiators
- —de novo antibody design against difficult targets
- —AI and computational modeling combined with structural biology
- —fast turnaround (weeks rather than months; historical claims as fast as hours/one week)
- —antibody humanization and epitope mapping
- —proprietary algorithms and custom antibody-design database
- —remote-deliverable computational workflow
Technology
AI/ML
computational modeling
proprietary algorithms
neural networks
structural modeling
antibody design software
online antibody workspace
3D molecular viewer
AES-128 encrypted submission
Apache
jQuery
HubSpot Analytics
Google Fonts API
Google Maps
PWA
Medium
Envoy
Customers
biotech partners
pharmaceutical partners
large biopharmaceutical companies
smaller biotechs
Cytovia Therapeutics
Competitors
EVQLV
MAbSilico
KSQ Therapeutics
METiS Therapeutics
NephroDI Therapeutics
Seer
Biognosys
Peptris
Praedicare Labs
ProteinSimple
Scale & contact
Estimated revenue
Public estimates conflict: about $210k/year (Growjo) to about $2.1M ARR (Latka)
Estimated monthly visits
828
Latest news
Medium · Oct 2020
Macromoltek discussed GPU-accelerated deep learning and NVIDIA/CUDA usage in antibody development, offering one of the clearest public windows into its technical stack and workflow.
Medium · Jun 2020
The company described how it kept antibody-design projects moving remotely during the pandemic, including a mix of engineering and lab work and more deliberate team coordination.
PR Newswire · Apr 2020
Macromoltek said it would apply its computational design platform to Cytovia Therapeutics' COVID-19 program, highlighting proprietary machine-learning/AI antibody design, remote delivery, and fast-track therapeutic candidate development.
PR Newswire · Apr 2020
Macromoltek announced a computational de novo antibody design offering for COVID-19, describing automated structural modeling and machine learning for rapid antibody design.
Jobs and careers at Macromoltek
0 jobs at Macromoltek
No open positions
Check back later for new openings